Drs. Karine Tawagi and Samantha Armstrong, known together as “The Two Onc Docs,” expand on the prostate cancer discussions of note from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, chief among them the long-term data from TALAPRO-2.
ASCO GU Prostate Updates: TALAPRO-2 and Other Considerations
By Karine Tawagi, MD, Samantha Armstrong, MD - Last Updated: February 24, 2025Related Posts
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
Using Decipher in the SPPORT Study: Determining Response to Randomized Post-Prostatectomy Salvage RT
Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.